Overcoming Immunotherapy Resistance Pathways in the Tumor Microenvironment

Overcoming Immunotherapy Resistance Pathways in the Tumor Microenvironment

Dr. Thomas F. Gajewski, professor of medicine, explains why T cell-inflamed tumor microenvironment may serve as a predictive biomarker for response to immunotherapies.  Dr. Gajewski also describes how STING agonists may provide means to deliberately initiate innate immune inflammation to promote an endogenous T cell response in non-T cell-inflamed tumors.  


Published

May 18, 2016

Created by

The University of Chicago Medicine

Related Presenters

Gajewski

Thomas Gajewski, MD

Professor of Medicine

Thomas Gajewski, MD, PhD, investigates and develops new treatments for patients with melanoma. He has a special interest in the development of immunotherapies against this disease. Dr. Gajewski also leads development of immune-based therapies ...